Will ‘Zemiglo’ handed to Daewoong change dynamics of the DPP-4 market?

As the domestic sales license of ‘Zemiglo,’ a domestic diabetes treatment which has been a hot potato since the beginning of this year, was passed to Daewoong Pharmaceutical, its future dynamic is expected to change.

According to the pharmaceutical industry on the 27^th, LG Life Sciences established a domestic joint marketing and sales license agreement of Zemiglo with Daewoong Pharmaceutical.